GlassScriptPhysician profile
Aruna Rokkam
NPI 1841333440
$9,327.53
in general payments reported to CMS, 2019-2025
57 companies · $2,862 in 2025
The $2,862 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $47.08 · 2020: $58.44 · 2021: $190 · 2022: $1,297 · 2023: $2,068 · 2024: $2,806 · 2025: $2,862.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,419 · Education: $316.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,419.08 |
| Education | $315.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $881.93 | 2022-2025 | |
| Janssen Biotech, INC. | $827.52 | 2019-2025 | Darzalex, Tecvayli, Talvey |
| Merck Sharp & Dohme LLC | $630.21 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Astrazeneca Pharmaceuticals LP | $544.96 | 2023-2025 | Enhertu, Lynparza, Calquence |
| Eisai INC. | $478.54 | 2021-2025 | |
| Gilead Sciences, INC. | $468.14 | 2021-2025 | Trodelvy |
| Takeda Pharmaceuticals U.S.A., INC. | $462.32 | 2022-2025 | Alunbrig, Iclusig, Ninlaro |
| Glaxosmithkline, LLC. | $456.11 | 2021-2025 | Ojjaara, Jemperli, Zejula |
| Abbvie INC. | $451.33 | 2022-2025 | Venclexta |
| Celgene Corporation | $397.05 | 2022-2025 | Reblozyl, Pomalyst, Opdualag |
| Novartis Pharmaceuticals Corporation | $356.19 | 2020-2025 | |
| Array Biopharma INC | $255.18 | 2022-2025 | Mektovi, Braftovi, Lorbrena |
| Genentech USA, INC. | $250.79 | 2019-2025 | Phesgo, Polivy, Lunsumio |
| Pharmacyclics LLC, An Abbvie Company | $224.44 | 2022-2023 | Imbruvica, Epkinly |
| Daiichi Sankyo INC. | $212.43 | 2022-2025 | Enhertu, Datroway |
Show all 56 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $170.45 | 2023-2025 | Vyloy, Padcev, Xospata |
| E.R. Squibb & Sons, L.L.C. | $157.56 | 2022-2025 | Opdivo, Opdualag, Krazati |
| Seagen INC. | $154.33 | 2021-2023 | Adcetris, Tukysa |
| Regeneron Healthcare Solutions, INC. | $147.79 | 2022-2025 | Libtayo |
| Incyte Corporation | $141.52 | 2021-2025 | Jakafi, Monjuvi |
| Aveo Pharmaceuticals, INC. | $125.01 | 2023-2024 | Fotivda |
| Genzyme Corporation | $109.51 | 2022-2025 | |
| Ipsen Biopharmaceuticals, INC | $104.44 | 2023-2025 | Onivyde, Tazverik |
| Tersera Therapeutics LLC | $98.42 | 2024-2025 | Zoladex |
| Karyopharm Therapeutics INC. | $95.34 | 2023-2025 | Xpovio |
| Taiho Oncology, INC. | $91.78 | 2023-2025 | |
| Pharmaessentia USA Corporation | $74.12 | 2022-2025 | Besremi |
| Puma Biotechnology, INC. | $68.84 | 2022-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $66.51 | 2025 | |
| Stemline Therapeutics INC. | $63.02 | 2023-2025 | Orserdu |
| Kite Pharma, INC. | $58.52 | 2022-2023 | |
| Legend Biotech USA INC. | $58.38 | 2025 | Carvykti |
| Jazz Pharmaceuticals INC. | $48.39 | 2024-2025 | |
| Genmab U.S., INC. | $47.24 | 2023-2024 | Tivdak, Epkinly |
| Lilly USA, LLC | $45.55 | 2024-2025 | Verzenio, Jaypirca |
| Exelixis INC. | $39.48 | 2024 | Cabometyx |
| Rigel Pharmaceuticals, INC. | $36.39 | 2023 | Tavalisse, Rezlidhia |
| Sobi, INC | $36.02 | 2023-2025 | |
| Kyowa Kirin, INC. | $33.72 | 2023-2024 | Poteligeo |
| Novocure INC. | $29.70 | 2021-2023 | Optune |
| Adaptive Biotechnologies Corporation | $29.56 | 2023 | Clonoseq |
| G1 Therapeutics, INC. | $28.89 | 2022-2023 | Cosela |
| Dendreon Pharmaceuticals LLC | $26.68 | 2025 | Provenge |
| Acrotech Biopharma INC. | $25.90 | 2021-2022 | |
| Geron Corporation | $24.85 | 2025 | Rytelo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.76 | 2023 | Gilotrif |
| Mirati Therapeutics, INC. | $24.43 | 2024 | Krazati |
| Amgen INC. | $18.34 | 2020 | |
| Springworks Therapeutics, INC. | $18.05 | 2024 | Ogsiveo |
| Foundation Medicine, INC. | $17.86 | 2023 | |
| Agios Pharmaceuticals, INC. | $16.31 | 2023 | Pyrukynd |
| Alexion Pharmaceuticals, INC. | $16.00 | 2024 | Ultomiris |
| Recordati_rare_diseases_inc. | $15.46 | 2025 | Sylvant |
| Blueprint Medicines Corporation | $15.00 | 2022 | |
| Pharmacosmos Therapeutics INC. | $13.52 | 2024 | Cosela |
| Global Blood Therapeutics, INC. | $12.75 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aruna Rokkam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.